Document Detail

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo.
MedLine Citation:
PMID:  22275986     Owner:  NLM     Status:  In-Data-Review    
Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a 'Stealth' (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.
Y Yuan; Sj Orlow; J Curtin; A Downey; F Muggia
Related Documents :
22912906 - Are multimorbidities underestimated in scoring systems of stevens-johnson syndrome and ...
25441286 - Delayed union of a jones fracture in a patient with rothmund-thomson syndrome: a case r...
23324646 - Dandy-walker malformation with postaxial polydactly: a new case of pierquin syndrome.
22275986 - Pegylated liposomal doxorubicin (pld): enhanced skin toxicity in areas of vitiligo.
24700646 - Interstitial 22q13 deletions not involving shank3 gene: a new contiguous gene syndrome.
1744496 - Superior vena cava syndrome associated with malignant mesothelioma.
Publication Detail:
Type:  Journal Article     Date:  2008-12-09
Journal Detail:
Title:  Ecancermedicalscience     Volume:  2     ISSN:  1754-6605     ISO Abbreviation:  Ecancermedicalscience     Publication Date:  2008  
Date Detail:
Created Date:  2012-01-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101392236     Medline TA:  Ecancermedicalscience     Country:  England    
Other Details:
Languages:  eng     Pagination:  111     Citation Subset:  -    
NYU Cancer Institute and Medical Oncology, NYU Langone Medical Center, New York, NY 10016, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers.
Next Document:  Cancer stem cells in melanoma.